Get the Stockscreener App
0.319
4.35%
-0.0145
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, on Innovative Targeted Therapies for Advanced - DocWire News
Cyclacel Pharmaceuticals amends agreement with CEO By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals amends agreement with CEO - Investing.com
(CYCCP) Trading Report - Stock Traders Daily
Head-To-Head Review: Cyclacel Pharmaceuticals (NASDAQ:CYCC) vs. Silence Therapeutics (NASDAQ:SLN) - Defense World
StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $25 million in funding from Helena Special Opportunities LLC - Marketscreener.com
Cyclacel stock plunges to 52-week low of $0.31 amid market challenges - MSN
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase - MSN
Cyclacel Pharmaceuticals adjusts shareholder rights, amends stock - Investing.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8 million in funding -February 03, 2025 - Marketscreener.com
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Announces Creditors Voluntary Liquidation Of UK Subsidiary - Marketscreener.com
How To Trade (CYCCP) - Stock Traders Daily
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com - Defense World
(CYCCP) On The My Stocks Page - Stock Traders Daily
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy - MSN
Cyclacel Pharmaceuticals Corrects Inadvertent Error in Securities Purchase Agreement - Defense World
How the (CYCCP) price action is used to our Advantage - Stock Traders Daily
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
Cyclacel Pharmaceuticals Announces Agreement for $3.1 Million Investment by David Lazar as Interim CEO - Defense World
Cyclacel Pharmaceuticals Restructures Leadership and Financial Strategy - TipRanks
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - citybiz
Stock market news: Nauticus Robotics gained 93.71% while N2OFF rose by 128.03% during mid day trading - Business Upturn
Cyclacel Pharmaceuticals, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
Why Cyclacel Pharmaceuticals (CYCC) Stock Is Skyrocketing - Benzinga
Cyclacel Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Dow Jumps Over 100 Points; ISM Manufacturing PMI Increases In December - Benzinga
David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps - Seeking Alpha
Cyclacel Pharmaceuticals Secures $3.1M Investment, Names David Lazar as Interim CEO Amid Restructuring - StockTitan
Royal Bank of Canada (RY-T) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
Trend Tracker for (CYCCP) - Stock Traders Daily
Cyclacel stock plunges to 52-week low, hits $0.32 - Investing.com India
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com - Defense World
Stock Watch: A Biotech Holiday Horror Story - Citeline News & Insights
Cyclacel Pharmaceuticals Faces Potential Delisting from Nasdaq Stock Market Due to Minimum Bid Price Noncompliance - Defense World
Trading (CYCCP) With Integrated Risk Controls - Stock Traders Daily
Cash-strapped Cyclacel cuts costs as it searches for financial lifeline - Fierce Biotech
Cyclacel Pharmaceuticals Exploring Alternatives, Cuts Costs to Preserve Cash - MarketWatch
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs - The Manila Times
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):